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a b s t r a c t
Cortical spreading depression (CSD) is a phenomenon implicated in migraine with aura and associated
with other neurological disorders (e.g. stroke, brain trauma). Current evidence points to the essential role
of NMDA receptors in CSD mechanisms. However, the roles of multiple subunits of NMDA receptors
expressed in neurons, glia and blood vessels in vivo, are little explored. Using BOLD fMRI of urethane
anesthetized rats as an integrative CSD readout, we tested the involvement of different NMDA receptor
subtypes in CSD induction and propagation. Rats were treated with a non-selective NMDA blocker (MK-
801), NR2B antagonist (ifenprodil) or a NR2A selective antagonist (TCN-201). CSD was induced during
fMRI scanning by application of KCl onto the cerebral cortex and fMRI data were collected by 9.4 T MRI.
The non-speciﬁc NMDA antagonist MK-801 completely blocked CSD, which was not observed in the
NR2A group where TCN-201 did not alter the CSD features. Unexpectedly, the NR2B speciﬁc antagonist
ifenprodil largely promoted the initial negative phase of the BOLD CSD response, likely due to altered
neurovascular coupling. Our data suggest key roles and differential involvement of NMDA receptor
subtypes in CSD generation and propagation, highlighting an important role for the NR2B subtype.
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Cortical spreading depression (CSD) is a self-propagating wave
of neuronal depolarization (Leao and Morison, 1945; Leao, 1944)
with glial and vascular involvement. (Charles and Baca, 2013) CSD is
associated with the massive release of various neurotransmitters,
dramatic shifts in ionic gradients and essential blood ﬂow. (Smith
et al., 2006) CSD takes place in a number of major neurological
disorders including stroke, brain trauma and notably, in migraine
with aura. (Dreier, 2011; Lauritzen et al., 2011). The primary role of
CSD in migraine with aura (MWA) was hypothesized by Leao and
Morrison (1945), Milner (Milner, 1958) and later conﬁrmed, using
the planar intracarotideal 133-Xenon method, SPECT and PET
(Lauritzen, 1994; Olesen et al., 1981; Woods et al., 1994).
Observation of CSD inMWApatients was also done using functional
MRI (Hadjikhani et al., 2001).
The excitatory neurotransmitter, glutamate, acting through via
ionotropic N-methyl-D-aspartate (NMDA) receptors, is currently
recognized as a key contributor to CSD induction and propagation
(Pietrobon and Moskowitz, 2013; Somjen, 2001). For these reasons,
NMDA receptors are a promising therapeutic target for clinical use.
The NMDA receptor is one of the most abundant receptors in the
mammalian brain, expressed in both neuronal and glial tissues
(Verkhratsky and Kirchhoff, 2007) as well as in cerebral arteriolar
endothelium (LeMaistre et al., 2012; Sharp et al., 2003). The re-
ceptor is a heterotetrameric ionotropic channel that is typically
comprised of different combinations of NR1 and NR2A-D or NR3A-
B subunits (Monyer et al., 1992; Paoletti and Neyton, 2007). In
particular, receptors with NR2A subunits normally mediate syn-
aptic transmission whereas NR2B containing receptors are mainly
expressed extrasynaptically (Sanz-Clemente et al., 2013) and in
astrocytes (Dzamba et al., 2013). A growing body of evidence
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